QFT-Plus: a plus in variability? - Evaluation of new generation IGRA in serial testing of students with a migration background in Germany

被引:32
作者
Knierer, J. [1 ]
Morales, E. N. Gallegos [1 ]
Schablon, A. [1 ]
Nienhaus, A. [1 ,2 ]
Kersten, J. F. [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf UKE, Ctr Excellence Hlth Serv Res Nursing CVcare, Hamburg, Germany
[2] Inst Statutory Accid Insurance & Prevent Hlth & W, Principles Prevent & Rehabil Dept GPR, Hamburg, Germany
关键词
Latent tuberculosis infection; QFT Plus; Variability; Serial testing; Students; GAMMA RELEASE ASSAYS; TUBERCULIN SKIN-TEST; HEALTH-CARE WORKERS; REPRODUCIBILITY; CONVERSION; INFECTION; DIAGNOSIS; RESPONSES; REVERSION;
D O I
10.1186/s12995-016-0148-z
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Currently available Interferon-gamma release assays (IGRAs) show a considerable variability in serial testing for latent tuberculosis infection (LTBI). This study offers first results for the new generation IGRA QuantiFERON-TB Gold Plus (QFT-Plus) introduced in 2015 in comparison with its predecessor QuantiFERON-TB Gold In-Tube (QFT-GIT) from serial testing of students with a migration background at German universities. Methods: Forty-one students were selected from a previous study. All students with a positive IGRA were asked and 11 agreed to participate in this cohort study. Additionally 30 students with negative IGRA results were selected by chance. Weekly testing with QFT-Plus and QFT-GIT was performed in all individuals over a 4-week period. IGRA variability was evaluated by calculating conversion and reversion rates. Results: From 41 participants a total number of 163 serial measurements were analyzed for each IGRA, leading to 122 possible IGRA changes each. QFT-Plus had four conversions and two reversions leading to a conversion rate of 4.3% (4 of 93 possible conversions, 95% CI 1.4-11.3%) and reversion rate of 6.9% (2 of 29 possible reversions, 95% CI 1.2-24.2%). QFT-GIT had 2 conversions and 1 reversion causing slightly lower rates with 2.2% conversions (2 of 91, 95% CI 0.4-8.5%) and 3.2% reversions (1 of 31, 95% CI 0.2-18.5%). Inconsistent IGRA results occurred in 4 subjects for QFT-Plus (8 stable positives, 29 stable negatives) and in 2 subjects for QFT-GIT (9 stable positives, 30 stable negatives). Agreement between the two IGRAs was 95.1% (kappa = 0.89). Variance attributed to the individuals was low (QFT-Plus: ICC = 0.88). Conclusion: This study confirms occurrence of conversions and reversions for the new QFT-Plus in serial testing of a high-risk cohort in a low-incidence setting with improbable new TB contact during the study. QFT-Plus conversion and reversion rates were slightly higher than for the QFT-GIT but overall they were lower for both IGRAs than in other studies that investigated IGRA variability.
引用
收藏
页数:12
相关论文
共 34 条
[1]   The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents [J].
Andrews, Jason R. ;
Hatherill, Mark ;
Mohamed, Hassan ;
Hanekom, Willem A. ;
Campo, Monica ;
Hawn, Thomas R. ;
Wood, Robin ;
Scriba, Thomas J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (05) :584-591
[2]   First independent evaluation of QuantiFERON-TB Plus performance [J].
Barcellini, Lucia ;
Borroni, Emanuele ;
Brown, James ;
Brunetti, Enrico ;
Codecasa, Luigi ;
Cugnata, Federica ;
Dal Monte, Paola ;
Di Serio, Clelia ;
Goletti, Delia ;
Lombardi, Giulia ;
Lipman, Marc ;
Rancoita, Paola M. V. ;
Tadolini, Marina ;
Cirillo, Daniela M. .
EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (05) :1587-1590
[3]   Regression to the mean: what it is and how to deal with it [J].
Barnett, AG ;
van der Pols, JC ;
Dobson, AJ .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2005, 34 (01) :215-220
[4]  
Cicchetti DV., 1994, PSYCHOL ASSESSMENTS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]
[5]   Evidence-Based Comparison of Commercial Interferon-γ Release Assays for Detecting Active TB [J].
Diel, Roland ;
Loddenkemper, Robert ;
Nienhaus, Albert .
CHEST, 2010, 137 (04) :952-968
[6]  
European Centre for Disease Prevention and Control, 2011, US INT GAMM REL ASS, P3
[7]   Impact of Blood Volume, Tube Shaking, and Incubation Time on Reproducibility of QuantiFERON-TB Gold In-Tube Assay [J].
Gaur, Rajiv L. ;
Pai, Madhukar ;
Banaei, Niaz .
JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (11) :3521-3526
[8]   T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen US Hospitals [J].
King, Thomas C. ;
Upfal, Mark ;
Gottlieb, Andrew ;
Adamo, Philip ;
Bernacki, Edward ;
Kadlecek, Chris P. ;
Jones, Jeffrey G. ;
Humphrey-Carothers, Frances ;
Rielly, Albert F. ;
Drewry, Pamela ;
Murray, Kathy ;
DeWitt, Marcie ;
Matsubara, Janet ;
O'Dea, Louis ;
Balser, John ;
Wrighton-Smith, Peter .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (03) :367-373
[9]  
Grummer-Strawn Laurence M., 2010, Morbidity and Mortality Weekly Report, V59, P1
[10]  
Nienhaus A, 2013, EXPERT REV ANTI-INFE, V11, P37, DOI [10.1586/eri.12.150, 10.1586/ERI.12.150]